Cai Xiao, Chen Xiu-Min, Xia Xuan, Bao Kun, Wang Rong-Rong, Peng Jian-Hong, Liu Hai-Jun, Yang Qiao-Wen, Yan Jing-Yao, Wang Mao-Jie, Yu Hua, Lu Jin-Jian, Hu Yuan-Jia, Jakobsson Per-Johan, Wen Ze-Huai, Huang Run-Yue, Huang Qing-Chun
The Second Clinical College, Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Department of Rheumatology, Dongguan Hospital of Traditional Chinese Medicine, Dongguan, China.
Front Pharmacol. 2018 Aug 30;9:914. doi: 10.3389/fphar.2018.00914. eCollection 2018.
Rheumatoid Arthritis (RA) is a systemic autoimmune disease leading to joint destruction. The prevention of bone and cartilage destruction has received increased attention in recent years. To evaluate the current evidences regarding the bone-protecting efficacy of Chinese medicine or the combination of Chinese medicine and Western medicine for RA. We comprehensively searched PubMed, Embase, the Cochrane Library (www.thecochranelibrary.com), the China National Knowledge Infrastructure (CNKI), the Database for Chinese Technical Periodicals (VIP), and SinoMed. We then performed a systematic review and cumulative meta-analysis of all randomized controlled trials (RCTs) assessing the two therapy methods. Sixteen studies including 1,171 patients were included in the final analysis. The results showed that Chinese medicine could significantly improve the bone mineral density (BMD) (mean difference [MD] = 0.05 /g·cm, 95% CI [0.03, 0.08], < 0.00001), and decrease the serum matrix metalloproteinase 3 (MMP-3) ([SMD] = -2.84, 95% CI [-4.22, -1.47], < 0.0001). Chinese medicine may provide an efficiently alternative choice for the treatment of RA in terms of the bone-protecting efficiency. Given the inherent limitations of the included studies, future well-designed RCTs are required to confirm and update the findings of this analysis.
类风湿关节炎(RA)是一种导致关节破坏的全身性自身免疫性疾病。近年来,预防骨和软骨破坏受到了越来越多的关注。为了评估关于中药或中西医结合治疗RA的骨保护疗效的现有证据,我们全面检索了PubMed、Embase、Cochrane图书馆(www.thecochranelibrary.com)、中国知网(CNKI)、中文科技期刊数据库(VIP)和中国生物医学文献数据库(SinoMed)。然后,我们对所有评估这两种治疗方法的随机对照试验(RCT)进行了系统评价和累积荟萃分析。最终分析纳入了16项研究,共1171例患者。结果表明,中药可显著提高骨密度(平均差[MD]=0.05/g·cm,95%可信区间[0.03,0.08],P<0.00001),并降低血清基质金属蛋白酶3(MMP-3)(标准化均数差[SMD]=-2.84,95%可信区间[-4.22,-1.47],P<0.0001)。就骨保护效率而言,中药可能为RA的治疗提供一种有效的替代选择。鉴于纳入研究的固有局限性,未来需要设计良好的RCT来证实和更新本分析的结果。